Theseus Pharmaceuticals (NASDAQ: THRX) enters a definitive merger agreement with Concentra Biosciences for $3.90 to $4.05 per share in cash, including a non-tradeable contingent value right. The deal, led by Tang Capital Partners, gains unanimous approval from Theseus’ Board. A subsidiary of Concentra will initiate a tender offer by January 9, 2024, subject to specific conditions. Expected closure in February 2024, supported by 59% of shareholders, involves advisory roles from Leerink Partners, Goodwin Procter LLP, and Gibson, Dunn & Crutcher LLP.
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (“Theseus” or the “Company”), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC (“Concentra”) will acquire Theseus for a price per share of Theseus common stock (“Theseus common stock”) of between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the “Base Price”) and (ii) an additional cash amount of not more than $0.15 per share at the closing of the merger (together with the Base Price, the “Cash Amount”), plus one non-tradeable contingent value right (“CVR”) representing the right to receive 80% of the net proceeds from any license or disposition of Theseus’ programs effected within 180 days of closing of the merger and 50% of the potential aggregate value of certain specified potential cost savings realized within 180 days of the close of the merger, pursuant to a Contingent Value Rights Agreement (the “CVR Agreement”).
Following a thorough review process conducted with the assistance of its legal and financial advisors, Theseus’ Board of Directors has determined that the acquisition by Concentra – of which Tang Capital Partners, LP is the controlling shareholder – is in the best interests of all Theseus shareholders, and has unanimously approved the Merger Agreement.
Pursuant and subject to the terms of the Merger Agreement, a wholly owned subsidiary of Concentra will commence a tender offer (the “Offer”) by January 9, 2024 to acquire all outstanding shares of Theseus common stock. Closing of the Offer is subject to certain conditions, including the tender of Theseus common stock representing at least a majority of the total number of outstanding shares; the availability of at least $187.6 million of cash, net of transaction costs, wind-down costs and other liabilities, at closing, and other customary closing conditions. Theseus shareholders holding approximately 59% of Theseus common stock have signed support agreements under which such shareholders agreed to tender their shares in the Offer and support the merger. The acquisition is expected to close in February 2024.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Advisors
Leerink Partners is acting as exclusive financial advisor and Goodwin Procter LLP is acting as legal counsel to Theseus. Gibson, Dunn & Crutcher LLP is acting as legal counsel to Concentra.
Source: Bio Space
